Hussein A. Tawbi, MD, PhD: COMBI-AD was a large, randomized, global phase III trial that took patients with nodal involvement, so stage III patients—it was patients with stage IIIa, IIIb, and IIIc in the AJCC [American Joint Committee on Cancer Cancer Staging Manual] 7th edition—and randomized them to dabrafenib and trametinib as active therapy versus placebo.
Archive | Video Reports
Trials and Treatment in Advanced Melanoma
Posted in Melanoma News, Health Professionals, Video Reports
Encorafenib/Binimetinib Combo Continues to Show Survival Benefit in BRAF-Mutant Melanoma
Long-term data from the COLUMBUS trial showed that encorafenib (Braftovi) plus binimetinib (Mektovi) had superior overall survival (OS) and progression-free survival (PFS) compared with encorafenib or vemurafenib (Zelboraf) alone in patients with BRAF V600–mutant melanoma.
Posted in Melanoma News, Health Professionals, Video Reports
An Instinct for Innovation Drives Robert’s Melanoma Research
For patients with melanoma, hope lies at the dermatology unit of Institut Gustave Roussy, located in the Paris suburb of Villejuif, France, and considered one of the world’s foremost cancer research centers.
Posted in Melanoma News, Health Professionals, Video Reports
Dr. Robert on Potential of Dabrafenib/Trametinib in Melanoma Brain Metastases
Caroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussey, co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University, explains why patients with melanoma and brain metastases were excluded from a trial evaluating the efficacy of dabrafenib (Tafinlar) plus trametinib (Mekinist).
Posted in Melanoma News, Health Professionals, Video Reports
